Key facts
- It has raised $1.7M; the latest was Accelerator/Incubator ($100K) in Jan 2025.
- Notable investors include Creative Destruction Lab, Federal Economic Development Agency for Southern Ontario, Innovation Factory (Hamilton), Angel One Investor Network, Archangel Network of Funds — 14 tracked in total.
- Status: Privately Held (backing).
Investors
14+- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Noa Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Noa Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Noa Therapeutics
Developer of a proprietary nuclear factor erythroid 2-related factor 2 (Nrf2)-biased platform designed to target the aryl hydrocarbon receptor, a key regulator of innate immunity and barrier homeostasis. The company offers selective modulation of receptor recruitment through coregulator engagement and co-recruitment of nuclear factor erythroid 2-related factor 2 to specific genes, enabling pharmaceutical researchers to achieve safe receptor activation and durable inflammation resolution without immunosuppression.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2022
- Employees
- 6
- Website
- noatherapeutics.com/
- Ownership
- Privately Held (backing)
Noa Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Noa Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Noa Therapeutics in its N-PORT filings yet. We sweep new filings monthly.